Evaluation of Irbesartan on Hepatic Fibrosis in Chronic Hepatitis C

Summary

The purpose of this study is to examine the efficacy of irbesartan on the progression of liver fibrosis in adult patients with chronic hepatitis C. The expected total enrollment is 200 patients. Patients who meet the study criteria and accept to participate at this study will take by day one tablet of 150 mg of treatment (irbesartan or placebo) during two years. The assessment of efficacy will be make by evaluation of area of liver fibrosis and blood markers of liver fibrosis

Timeline

Start

2006-10

Primary completion

2013-04

Completion

2013-11

Publications

• Results Cales, Paul, et al. "Irbesartan for severe fibrosis in chronic hepatitis C: a double-blind randomized trial (ANRS HC19 Fibrosar): 454." Hepatology 60 (2014): 423A-424A.

Drugs

Indications